PharmaShots | Incisive News in 3 Shots

Subscribe Now

Aleta Biotherapeutics

$Aleta Biotherapeutics Reports First Patient Dosing with ALETA-001 in P-I/II Study for Treating Relapsed/Refractory B-Cell Malignancies$

Aleta Biotherapeutics Reports First Patient Dosing with ALETA-001 in P-I/II Study for Treating Relapsed/Refractory B-Cell Malignan...

February 22, 2024

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us